A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
There are currently no pharmacological treatments approved to treat borderline personality
disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of
brexpiprazole for the treatment of subjects diagnosed with BPD to provide a pharmacological
treatment for BPD.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.